Citation Impact
Citing Papers
Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial
2010 StandoutNobel
Intracellular Tumor-Associated Antigens Represent Effective Targets for Passive Immunotherapy
2012 StandoutNobel
Enhancement of Tumor-Reactive Cytotoxic CD4+ T-cell Responses after Ipilimumab Treatment in Four Advanced Melanoma Patients
2013 StandoutNobel
Immune Cell–Poor Melanomas Benefit from PD-1 Blockade after Targeted Type I IFN Activation
2014
Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial
2011 Standout
Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update 2014
2015 Standout
Genetic Evolution of T-cell Resistance in the Course of Melanoma Progression
2014
Two Distinct Mechanisms of Augmented Antitumor Activity by Modulation of Immunostimulatory/Inhibitory Signals
2010 StandoutNobel
Multicenter Phase III Comparison of Cisplatin/S-1 With Cisplatin/Infusional Fluorouracil in Advanced Gastric or Gastroesophageal Adenocarcinoma Study: The FLAGS Trial
2010
Reciprocal Regulation of DUSP9 and DUSP16 Expression by HIF1 Controls ERK and p38 MAP Kinase Activity and Mediates Chemotherapy-Induced Breast Cancer Stem Cell Enrichment
2018 StandoutNobel
Expert opinion on management of gastric and gastro-oesophageal junction adenocarcinoma on behalf of the European Organisation for Research and Treatment of Cancer (EORTC) - gastrointestinal cancer group
2008
Pembrolizumab alone or in combination with chemotherapy as first-line therapy for patients with advanced gastric or gastroesophageal junction adenocarcinoma: results from the phase II nonrandomized KEYNOTE-059 study
2019
Docetaxel plus oxaliplatin with or without fluorouracil or capecitabine in metastatic or locally recurrent gastric cancer: a randomized phase II study
2014
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial
2010 Standout
Gastric cancer
2016 Standout
Killing cancer cells by targeted drug-carrying phage nanomedicines
2008
Acetylation of Stat1 modulates NF-κB activity
2006
Optimal chemotherapy for advanced gastric cancer: is there a global consensus?
2013
Quality of life of older adult patients receiving docetaxel-based chemotherapy triplets for esophagogastric adenocarcinoma: a randomized study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)
2013
Cisplatin or Not in Advanced Gastric Cancer: A Systematic Review and Meta-Analysis
2013
Perioperative Chemotherapy versus Surgery Alone for Resectable Gastroesophageal Cancer
2006 Standout
A randomized phase II study of weekly docetaxel/cisplatin versus weekly docetaxel/oxaliplatin as first-line therapy for patients with advanced gastric cancer
2013
A randomised phase II study of combination chemotherapy with epirubicin, cisplatin and capecitabine (ECX) or cisplatin and capecitabine (CX) in advanced gastric cancer
2010
Histone Deacetylase Inhibitors in the Treatment of Hematological Malignancies and Solid Tumors
2010
Cancer nanomedicine: progress, challenges and opportunities
2016 Standout
Mesoporous silica nanoparticles in biomedical applications
2012 StandoutNobel
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial
2013
The evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
2019 Standout
Nanoparticle therapeutics: an emerging treatment modality for cancer
2008 Standout
A randomized phase II trial of S-1-oxaliplatin versus capecitabine–oxaliplatin in advanced gastric cancer
2012
The feasibility of triple-drug chemotherapy combination in older adult patients with oesophagogastric cancer: A randomised trial of the Arbeitsgemeinschaft Internistische Onkologie (FLOT65+)
2012
Cancer Epigenetics: From Mechanism to Therapy
2012 Standout
Addition of docetaxel to S-1 without platinum prolongs survival of patients with advanced gastric cancer: a randomized study (START)
2013
Vaccines for established cancer: overcoming the challenges posed by immune evasion
2016
Interferons Induce CXCR3-cognate Chemokine Production by Human Metastatic Melanoma
2010
Immunogenic cell death in cancer and infectious disease
2016 Standout
Chemotherapy for advanced gastric cancer
2010
Cancer stem cells revisited
2017 Standout
Chemotherapy-induced peripheral neurotoxicity (CIPN): An update
2011
PHAST: A Fast Phage Search Tool
2011 Standout
Epitope clustering in regions undergoing efficient proteasomal processing defines immunodominant CTL regions of a tumor antigen
2006
Mammalian display screening of diverse cystine-dense peptides for difficult to drug targets
2017 StandoutNobel
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2016
Single-agent treatment with pegylated liposomal doxorubicin for metastatic breast cancer
2008
Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study
2009
Cytotoxic chemotherapy: Still the mainstay of clinical practice for all subtypes metastatic breast cancer
2016
Novel cancer immunotherapy agents with survival benefit: recent successes and next steps
2011 StandoutNobel
Cancer testis antigen expression in gastrointestinal stromal tumors: New markers for early recurrence
2008
Epigenetic treatment of solid tumours: a review of clinical trials
2015
Docetaxel plus cisplatin and S-1 versus cisplatin and S-1 in patients with advanced gastric cancer (JCOG1013): an open-label, phase 3, randomised controlled trial
2019
Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy
2016 Standout
A randomized multicenter phase II study comparing capecitabine with irinotecan or cisplatin in metastatic adenocarcinoma of the stomach or esophagogastric junction
2009
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
NY‐ESO‐1: Review of an Immunogenic Tumor Antigen
2006
Adjuvant capecitabine and oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): a phase 3 open-label, randomised controlled trial
2012 Standout
Gastric cancer
2020 Standout
Effect of Duloxetine on Pain, Function, and Quality of Life Among Patients With Chemotherapy-Induced Painful Peripheral Neuropathy
2013 Standout
Capecitabine in combination with Oxaliplatin (XELOX) as a first-line therapy for advanced gastric cancer
2007
Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Targeting autophagy in cancer
2017 Standout
Paul Ehrlich's magic bullet concept: 100 years of progress
2008 Standout
Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma
2022
Paclitaxel based vs oxaliplatin based regimens for advanced gastric cancer
2011
Regulatory T cells in tumor immunity
2010 StandoutNobel
Therapeutic Cancer Vaccines
2013
Advanced gastric cancer: Current treatment landscape and future perspectives
2016
Imatinib potentiates antitumor T cell responses in gastrointestinal stromal tumor through the inhibition of Ido
2011 StandoutNobel
Favorable outcome in clinically stage II melanoma patients is associated with the presence of activated tumor infiltrating T‐lymphocytes and preserved MHC class I antigen expression
2008
Challenges in first line chemotherapy and targeted therapy in advanced gastric cancer
2014
Phase II study of NK105, a paclitaxel-incorporating micellar nanoparticle, for previously treated advanced or recurrent gastric cancer
2011
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Engineered Nanoparticles for Drug Delivery in Cancer Therapy
2014 Standout
Hepatocellular carcinoma
2022 Standout
Randomized Phase III Study of 5-Fluorouracil Continuous Infusion vs. Sequential Methotrexate and 5-Fluorouracil Therapy in Far Advanced Gastric Cancer with Peritoneal Metastasis (JCOG0106)
2013
Integrating cell-signalling pathways with NF-κB and IKK function
2006 Standout
Photothermal therapy and photoacoustic imaging via nanotheranostics in fighting cancer
2018 Standout
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Thromboembolism in Patients With Advanced Gastroesophageal Cancer Treated With Anthracycline, Platinum, and Fluoropyrimidine Combination Chemotherapy: A Report From the UK National Cancer Research Institute Upper Gastrointestinal Clinical Studies Group
2009
DEC-205 receptor on dendritic cells mediates presentation of HIV gag protein to CD8 + T cells in a spectrum of human MHC I haplotypes
2007 StandoutNobel
Integrated NY-ESO-1 antibody and CD8+T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab
2011 StandoutNobel
Weekly Infusional High-Dose Fluorouracil (HD-FU), HD-FU Plus Folinic Acid (HD-FU/FA), or HD-FU/FA Plus Biweekly Cisplatin in Advanced Gastric Cancer: Randomized Phase II Trial 40953 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group and the Arbeitsgemeinschaft Internistische Onkologie
2007
Cancer/testis antigens are novel targets of immunotherapy for adult T-cell leukemia/lymphoma
2012 StandoutNobel
Risk of Venous Thromboembolism in Patients With Cancer Treated With Cisplatin: A Systematic Review and Meta-Analysis
2012
Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion
2011 StandoutScience
Addition of rapamycin and hydroxychloroquine to metronomic chemotherapy as a second line treatment results in high salvage rates for refractory metastatic solid tumors: a pilot safety and effectiveness analysis in a small patient cohort
2015
Immunogenicity of therapeutic recombinant immunotoxins
2016
Chemotherapy for advanced gastric cancer
2017 Standout
High Incidence of Thromboembolic Events in Patients Treated With Cisplatin-Based Chemotherapy: A Large Retrospective Analysis
2011
Multiple roles for CD4+ T cells in anti‐tumor immune responses
2008
IFN-γ enables cross-presentation of exogenous protein antigen in human Langerhans cells by potentiating maturation
2004
Neoadjuvant Chemotherapy Compared With Surgery Alone for Locally Advanced Cancer of the Stomach and Cardia: European Organisation for Research and Treatment of Cancer Randomized Trial 40954
2010
Results of a randomized and controlled clinical trial evaluating the efficacy and safety of combination therapy with Endostar and S-1 combined with oxaliplatin in advanced gastric cancer
2013
Anti-CCR4 mAb selectively depletes effector-type FoxP3+CD4+regulatory T cells, evoking antitumor immune responses in humans
2013 StandoutNobel
Docetaxel and Continuous-Infusion Fluorouracil Versus Epirubicin, Cisplatin, and Fluorouracil for Advanced Gastric Adenocarcinoma: A Randomized Phase II Study
2005
Recombinant vaccinia/fowlpox NY-ESO-1 vaccines induce both humoral and cellular NY-ESO-1-specific immune responses in cancer patients
2006
CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
2008 StandoutNobel
Prospective, Randomized, Multicenter, Phase III Study of Fluorouracil, Leucovorin, and Irinotecan Versus Epirubicin, Cisplatin, and Capecitabine in Advanced Gastric Adenocarcinoma: A French Intergroup (Fédération Francophone de Cancérologie Digestive, Fédération Nationale des Centres de Lutte Contre le Cancer, and Groupe Coopérateur Multidisciplinaire en Oncologie) Study
2014
IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
2017 Standout
Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer.
2003
Multipronged Design of Light-Triggered Nanoparticles To Overcome Cisplatin Resistance for Efficient Ablation of Resistant Tumor
2015
Differential control of human Treg and effector T cells in tumor immunity by Fc-engineered anti–CTLA-4 antibody
2018 StandoutNobel
Works of Akin Atmaca being referenced
Efficient In vivo Priming by Vaccination with Recombinant NY-ESO-1 Protein and CpG in Antigen Naïve Prostate Cancer Patients
2010
Valproic acid (VPA) in patients with refractory advanced cancer: a dose escalating phase I clinical trial
2007
Phase I clinical study of the recombinant antibody toxin scFv(FRP5)-ETA specific for the ErbB2/HER2 receptor in patients with advanced solid malignomas
2005
The clinical benefit of pegylated liposomal doxorubicin in patients with metastatic breast cancer previously treated with conventional anthracyclines: a multicentre phase II trial
2006
Pathological complete remission in patients with oesophagogastric cancer receiving preoperative 5‐fluorouracil, oxaliplatin and docetaxel
2011
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
2018
Biweekly fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT) for patients with metastatic adenocarcinoma of the stomach or esophagogastric junction: a phase II trial of the Arbeitsgemeinschaft Internistische Onkologie
2008
Phase III Trial in Metastatic Gastroesophageal Adenocarcinoma with Fluorouracil, Leucovorin Plus Either Oxaliplatin or Cisplatin: A Study of the Arbeitsgemeinschaft Internistische Onkologie
2008
LUD 00-009: phase 1 study of intensive course immunization with NY-ESO-1 peptides in HLA-A2 positive patients with NY-ESO-1-expressing cancer.
2007
Reduced Incidence of Severe Palmar-Plantar Erythrodysesthesia and Mucositis in a Prospective Multicenter Phase II Trial with Pegylated Liposomal Doxorubicin at 40 mg/m<sup>2</sup> Every 4 Weeks in Previously Treated Patients with Metastatic Breast Cancer
2006
Whole-body hyperthermia (WBH) in combination with carboplatin in patients with recurrent ovarian cancer — A phase II study
2008
Identification of a naturally processed NY-ESO-1 peptide recognized by CD8+ T cells in the context of HLA-B51
2002
Urine antibody against human cancer antigen NY-ESO-1
2002
Intratumoral T-Cell Infiltrates and MHC Class I Expression in Patients with Stage IV Melanoma
2005
Phase I study of everolimus and mitomycin C for patients with metastatic esophagogastric adenocarcinoma
2013
Phase II Trial of Biweekly Infusional Fluorouracil, Folinic Acid, and Oxaliplatin in Patients With Advanced Gastric Cancer
2004